Granahan Investment Management’s Viking Therapeutics VKTX Stock Holding History

Granahan Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.8M	Buy	332,192 +96,606	+41%	+$3.11M	0.52%	52
2025 Q4	$8.29M	Buy	235,586 +46,057	+24%	+$1.63M	0.35%	69
2025 Q3	$4.98M	Sell	189,529 -115,562	-38%	-$3.45M	0.2%	99
2025 Q2	$8.08M	Sell	305,091 -62,870	-17%	-$1.66M	0.33%	75
2025 Q1	$8.89M	Buy	367,961 +62,375	+20%	+$1.97M	0.44%	66
2024 Q4	$12.3M	Sell	305,586 -19,701	-6%	-$1.12M	0.51%	57
2024 Q3	$20.6M	Sell	325,287 -53,411	-14%	-$3.13M	0.81%	35
2024 Q2	$20.1M	Buy	378,698 +59,805	+19%	+$3.92M	0.8%	37
2024 Q1	$26.1M	Buy	+318,893	New	+$14.2M	0.92%	30

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Granahan Investment Management's VKTX Position: Q1 2026 in Review

Granahan Investment Management increased its Viking Therapeutics (VKTX) stake by 41% in Q1 2026, buying an estimated $3.11M and bringing the position to 332,192 shares worth $10.8M. The position accounts for 0.52% of the portfolio, ranked #52.

Granahan Investment Management first reported a position in VKTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $26.1M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Granahan Investment Management held 332,192 shares of Viking Therapeutics worth $10.8M as of Q1 2026.
Granahan Investment Management bought 96,606 Viking Therapeutics shares in Q1 2026, an estimated $3.11M.
Viking Therapeutics made up 0.52% of Granahan Investment Management's portfolio in Q1 2026, its #52 holding.
Granahan Investment Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 9 quarters since.
Granahan Investment Management's Viking Therapeutics position peaked at $26.1M in Q1 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.